Distinct cerebral lesions in sporadic and 'D90A' SOD1 ALS: studies with [11C]flumazenil PET.

Five to ten percent of amyotrophic lateral sclerosis (ALS) cases are associated with mutations of the superoxide dismutase-1 (SOD1) gene, and the 'D90A' mutation is associated with a unique phenotype and markedly slower disease progression (mean survival time 14 years). Relative sparing of inhibitory cortical neuronal circuits might be one mechanism contributing to the slower progression in patients homozygous for the D90A mutation (homD90A). The GABA(A) receptor PET ligand [11C]flumazenil has demonstrated motor and extra-motor cortical changes in sporadic ALS. In this study, we used [11C]flumazenil PET to explore differences in the pattern of cortical involvement between sporadic and genetically homogeneous ALS groups. Twenty-four sporadic ALS (sALS) and 10 homD90A patients underwent [11C]flumazenil PET of the brain. In addition, two subjects homozygous for the D90A mutation, but without symptoms or signs ('pre-symptomatic', psD90A), also underwent imaging. Results for each group were compared with those for 24 healthy controls of similar age. Decreases in the binding of [11C]flumazenil in the sALS group were found within premotor regions, motor cortex and posterior motor association areas. In the homD90A group of ALS patients, however, decreases were concentrated in the left fronto-temporal junction and anterior cingulate gyrus. In the two psD90A subjects, a small focus of reduced [11C]flumazenil binding at the left fronto-temporal junction was seen, similar to the pattern seen in the clinically affected patients. Within the sALS group, there was no statistically significant association between decreases in cortical [11C]flumazenil binding and revised ALS functional rating scale (ALSFRS-R score), whereas the upper motor neuron (UMN) score correlated with widespread and marked cortical decreases over the dominant hemisphere. In the homD90A group, there was a stronger statistical association between reduced cortical [11C]flumazenil binding and the ALSFRS-R, rather than the UMN, score, and also with disease duration. This study provides evidence for differences in the distribution of reduced cortical [11C]flumazenil binding in homD90A compared with sALS patients. We hypothesize that this might reflect differences in cortical neuronal vulnerability.

[1]  M. Kaga,et al.  Abnormal cortical excitability in Rett syndrome. , 1993, Pediatric neurology.

[2]  G. Nicholson,et al.  Normal complement of motor units in asymptomatic familial (SOD1 mutation) amyotrophic lateral sclerosis carriers , 2001, Journal of neurology, neurosurgery, and psychiatry.

[3]  F. Turkheimer,et al.  Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study , 2004, Neurobiology of Disease.

[4]  P N Leigh,et al.  Frontal lobe dysfunction in amyotrophic lateral sclerosis. A PET study. , 1996, Brain : a journal of neurology.

[5]  P. Andersen,et al.  Autosomal recessive adult-onset amyotrophic lateral sclerosis associated with homozygosity for Asp90Ala CuZn-superoxide dismutase mutation. A clinical and genealogical study of 36 patients. , 1996, Brain : a journal of neurology.

[6]  M A Horsfield,et al.  Diffusion tensor MRI assesses corticospinal tract damage in ALS , 1999, Neurology.

[7]  P N Leigh,et al.  Extramotor involvement in ALS: PET studies with the GABA(A) ligand [(11)C]flumazenil. , 2000, Brain : a journal of neurology.

[8]  P N Leigh,et al.  Cortical function in amyotrophic lateral sclerosis. A positron emission tomography study. , 1993, Brain : a journal of neurology.

[9]  D. Lewis.  GABAergic local circuit neurons and prefrontal cortical dysfunction in schizophrenia , 2000, Brain Research Reviews.

[10]  Motor neuron disease. , 1994 .

[11]  C. Heckman,et al.  Hyperexcitability of cultured spinal motoneurons from presymptomatic ALS mice. , 2004, Journal of neurophysiology.

[12]  J. Haines,et al.  Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis , 1993, Nature.

[13]  J. Cedarbaum,et al.  The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function , 1999, Journal of the Neurological Sciences.

[14]  D. Arnold,et al.  Detection of cortical neuron loss in motor neuron disease by proton magnetic resonance spectroscopic imaging in vivo , 1994, Neurology.

[15]  P. Andersen,et al.  Phenotypic heterogeneity in motor neuron disease patients with CuZn-superoxide dismutase mutations in Scandinavia. , 1997, Brain : a journal of neurology.

[16]  N. Smyrnis,et al.  Frontal lobe dysfunction in amyotrophic lateral sclerosis , 2002, Journal of the Neurological Sciences.

[17]  J. Powell,et al.  D90A‐SOD1 mediated amyotrophic lateral sclerosis: A single founder for all cases with evidence for a Cis‐acting disease modifier in the recessive haplotype , 2002, Human mutation.

[18]  H. Herzog,et al.  Frontal lobe function in amyotrophic lateral sclerosis: a neuropsychologic and positron emission tomography study , 1992, Acta neurologica Scandinavica.

[19]  Morris Freedman,et al.  Frontal lobe functions , 2001, Current neurology and neuroscience reports.

[20]  P. Andersen.  Chapter 8 Genetic Aspects of Amyotrophic Lateral Sclerosis/Motor Neuron Disease , 2003 .

[21]  L. Goldstein,et al.  Verbal fluency and executive dysfunction in amyotrophic lateral sclerosis (ALS) , 2000, Neuropsychologia.

[22]  Zafiris J Daskalakis,et al.  Transcranial magnetic stimulation: a new investigational and treatment tool in psychiatry. , 2002, The Journal of neuropsychiatry and clinical neurosciences.

[23]  Marion C. Smith.  NERVE FIBRE DEGENERATION IN THE BRAIN IN AMYOTROPHIC LATERAL SCLEROSIS , 1960, Journal of neurology, neurosurgery, and psychiatry.

[24]  M. S. Young,et al.  Transcranial magnetic stimulation identifies upper motor neuron involvement in motor neuron disease , 1999, Neurology.

[25]  S. Landau,et al.  Cortical selective vulnerability in motor neuron disease: a morphometric study. , 2004, Brain : a journal of neurology.

[26]  G. Forster,et al.  Corticospinal tract degeneration in the progressive muscular atrophy variant of ALS , 2003, Neurology.

[27]  T. Yokota,et al.  Double cortical stimulation in amyotrophic lateral sclerosis. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[28]  S. Petri,et al.  Distribution of GABAA Receptor mRNA in the Motor Cortex of ALS Patients , 2003, Journal of neuropathology and experimental neurology.

[29]  E. T. Bullmore,et al.  Volumetric analysis reveals corticospinal tract degeneration and extramotor involvement in ALS , 2001, Neurology.

[30]  P. Andersen,et al.  Preserved slow conducting corticomotoneuronal projections in amyotrophic lateral sclerosis with autosomal recessive D90A CuZn-superoxide dismutase mutation. , 2000, Brain : a journal of neurology.

[31]  B. Miller,et al.  Are amyotrophic lateral sclerosis patients cognitively normal? , 2003, Neurology.

[32]  Karl J. Friston,et al.  Comparing Functional (PET) Images: The Assessment of Significant Change , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[33]  S. Zierz,et al.  Transcranial magnetic stimulation compared with upper motor neuron signs in patients with amyotrophic lateral sclerosis , 1999, Journal of the Neurological Sciences.

[34]  P. Massman,et al.  Prevalence and correlates of neuropsychological deficits in amyotrophic lateral sclerosis. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[35]  J. Kew,et al.  Dementia with motor neurone disease. , 1992, Bailliere's clinical neurology.

[36]  P N Leigh,et al.  The relationship between abnormalities of cognitive function and cerebral activation in amyotrophic lateral sclerosis. A neuropsychological and positron emission tomography study. , 1993, Brain : a journal of neurology.

[37]  M. Swash,et al.  El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis , 2000, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[38]  T. Jones,et al.  Spectral Analysis of Dynamic PET Studies , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[39]  J. Hodges,et al.  The effects of motor neurone disease on language: Further evidence , 2004, Brain and Language.

[40]  T. Neylan.  Frontal lobe function: Mr. Phineas Gage's famous injury. , 1999, The Journal of neuropsychiatry and clinical neurosciences.

[41]  A Al-Chalabi,et al.  Abnormal cortical excitability in sporadic but not homozygous D90A SOD1 ALS , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[42]  W. Paulus,et al.  Impaired motor cortex inhibition in patients with amyotrophic lateral sclerosis , 1997, Neurology.

[43]  Catherine Lomen-Hoerth,et al.  The overlap of amyotrophic lateral sclerosis and frontotemporal dementia , 2002, Neurology.

[44]  Robert H. Brown,et al.  Sixteen novel mutations in the Cu/Zn superoxide dismutase gene in amyotrophic lateral sclerosis: a decade of discoveries, defects and disputes. , 2003, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[45]  P. Sham,et al.  Recessive amyotrophic lateral sclerosis families with the D90A SOD1 mutation share a common founder: evidence for a linked protective factor. , 1998, Human molecular genetics.

[46]  R. Hanajima,et al.  Impaired motor cortex inhibition in patients with ALS , 1998, Neurology.

[47]  T. Siddique,et al.  Genetic aspects of amyotrophic lateral sclerosis. , 2002, Advances in neurology.